SARS-CoV-2 Spike Protein RBD (S477N Mutation)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein Receptor-Binding Domain (RBD) is a recombinant protein expressed in Mammalian cells.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The S477N mutation has been reported to increase binding to human ACE2.
The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the Spike Protein and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action.
The S477N mutation has been reported to increase binding to human ACE2.
| Supplier | Abbexa Ltd. |
|---|---|
| Product # | abx620008-100UG |
| Pricing | 100 µg USD $478.5 |
| Conjugation | Unconjugated |
| Host | Mammalian cells |
| Tested Applications | SDS-PAGE |
| Dry Ice | No |
| Availability | Shipped within 5-10 working days. |
| Note |
|